Evidence map›Paper›PMID 36906656›Full record

ArticleSchizophrenia (Heidelberg, Germany)2023

Urinary exosomal microRNAs as predictive biomarkers for persistent psychotic-like experiences.

Yasufumi Tomita, Kazuhiro Suzuki, Syudo Yamasaki, Kazuya Toriumi, Mitsuhiro Miyashita, Shuntaro Ando, Kaori Endo, Akane Yoshikawa, Koichi Tabata, Satoshi Usami and 6 more

Open access · diamondFull text read
In one paragraph

Article in Schizophrenia (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Yasufumi Tomita *Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kazuhiro Suzuki *Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Syudo YamasakiUnit for Mental Health Promotion, Research Center for Social Science and Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9016-6404
Kazuya ToriumiSchizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8593-3269
Mitsuhiro MiyashitaSchizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7798-1834
Shuntaro AndoDepartment of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1595-693X
Kaori EndoUnit for Mental Health Promotion, Research Center for Social Science and Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0854-5120
Akane YoshikawaDepartment of Psychiatry and Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Koichi TabataSchizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Satoshi UsamiCenter for Research and Development on Transition from Secondary to Higher Education, The University of Tokyo, Tokyo, Japan.
Mariko Hiraiwa-HasegawaDepartment of Evolutionary Studies of Biosystems, The Graduate University for the Advanced Studies, SOKENDAI, Hayama, Japan.
Masanari ItokawaSchizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Hideya KawajiResearch Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID http://orcid.org/0000-0002-0575-0308
Kiyoto KasaiDepartment of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4443-4535
Atsushi NishidaUnit for Mental Health Promotion, Research Center for Social Science and Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. nishida-at@igakuken.or.jp.
Makoto AraiSchizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. arai-mk@igakuken.or.jp.ORCID http://orcid.org/0000-0003-3400-9815
Tokyo Metropolitan Matsuzawa Hospital · JPTokyo Metropolitan Institute of Medical Science · JPThe University of Tokyo · JPJuntendo University · JPShinshu University · JPThe Graduate University for Advanced Studies, SOKENDAI · JPTokyo Medical and Dental University · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP18dm0307001Japan Agency for Medical Research and Development (AMED) JP18dm0307004Japan Agency for Medical Research and Development (AMED) JP19dm0207069Japan Agency for Medical Research and Development (AMED) JPMJMS2021MEXT | Japan Science and Technology Agency (JST) JPMJMI21J3MEXT | Japan Society for the Promotion of Science (JSPS) JP16H05380MEXT | Japan Society for the Promotion of Science (JSPS) JP16H06395MEXT | Japan Society for the Promotion of Science (JSPS) JP16H06395,MEXT | Japan Society for the Promotion of Science (JSPS) JP16H06398MEXT | Japan Society for the Promotion of Science (JSPS) JP16H06399MEXT | Japan Society for the Promotion of Science (JSPS) JP16K15566,MEXT | Japan Society for the Promotion of Science (JSPS) JP16K21720MEXT | Japan Society for the Promotion of Science (JSPS) JP17H05930MEXT | Japan Society for the Promotion of Science (JSPS) JP17H05931MEXT | Japan Society for the Promotion of Science (JSPS) JP18K07579MEXT | Japan Society for the Promotion of Science (JSPS) JP18K15354MEXT | Japan Society for the Promotion of Science (JSPS) JP19H03589MEXT | Japan Society for the Promotion of Science (JSPS) JP19H04877MEXT | Japan Society for the Promotion of Science (JSPS) JP19H04887MEXT | Japan Society for the Promotion of Science (JSPS) JP19K17055MEXT | Japan Society for the Promotion of Science (JSPS) JP20H01777MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03596MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03608MEXT | Japan Society for the Promotion of Science (JSPS) JP20H03951MEXT | Japan Society for the Promotion of Science (JSPS) JP21H05171MEXT | Japan Society for the Promotion of Science (JSPS) JP21H05173MEXT | Japan Society for the Promotion of Science (JSPS) JP21H05174MEXT | Japan Society for the Promotion of Science (JSPS) P16H03745
6 · The paper itself

Abstract

Psychotic-like experiences (PLEs) occur occasionally in adolescence and mostly disappear with increasing age. Their presence, if persistent, is considered a robust risk factor for subsequent psychiatric disorders. To date, only a few biological markers have been investigated for persistent PLE prediction. This study identified urinary exosomal microRNAs that can serve as predictive biomarkers for persistent PLEs. This study was part of a population-based biomarker subsample study of the Tokyo Teen Cohort Study. A total of 345 participants aged 13 (baseline) and 14 (follow-up) years underwent PLE assessments by experienced psychiatrists using semi-structured interviews. We defined remitted and persistent PLEs based on longitudinal profiles. We obtained urine at baseline and the expression levels of urinary exosomal miRNAs were compared between 15 individuals with persistent PLEs and 15 age- and sex-matched individuals with remitted PLEs. We constructed a logistic regression model to examine whether miRNA expression levels could predict persistent PLEs. We identified six significant differentially expressed microRNAs, namely hsa-miR-486-5p, hsa-miR-199a-3p, hsa-miR-144-5p, hsa-miR-451a, hsa-miR-143-3p, and hsa-miR-142-3p. The predictive model showed an area under the curve of 0.860 (95% confidence interval: 0.713-0.993) for five-fold cross-validation. We found a subset of urinary exosomal microRNAs that were differentially expressed in persistent PLEs and presented the likelihood that a microRNA-based statistical model could predict them with high accuracy. Therefore, urine exosomal miRNAs may serve as novel biomarkers for the risk of psychiatric disorders.

Identifiers

PMID36906656
PMCPMC10008540
OpenAlexW4323924910

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read34
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.